Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 6:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Anticoagulation Clear all
Completed Not applicable Interventional

Fondaparinux as Monotherapy for DVT and/or Pulmonary Embolism

NCT00413504
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolism
Interventions
Fondaparinux
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 3, 2009 · Synced Sep 14, 2026, 6:03 AM EDT
Completed Not applicable Interventional Results available

Remote Home Prothrombin Time (PT)/International Normalized Ratio (INR) Monitoring and Patient Management System

NCT00978445
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
vMetrics protocol
Other
Lead sponsor
ZIN Technologies, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 20, 2013 · Synced Sep 14, 2026, 6:03 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome

NCT00809965
View directory record Official record
Conditions
Acute Coronary Syndrome, Myocardial Infarction, Myocardial Ischemia, Unstable Angina
Interventions
Rivaroxaban 2.5 mg, Rivaroxaban 5 mg, Placebo, Standard of care
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
15,526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
73
States / cities
Birmingham, Alabama • Geneva, Alabama • Mobile, Alabama + 70 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Sep 14, 2026, 6:03 AM EDT
Not listed No phase listed Observational

Association of Genetic Variants With Risk of Stroke in Patients With Atrial Fibrillation Off-anticoagulation

NCT04115436
View directory record Official record
Conditions
Thromboembolic Events
Interventions
Not listed
Lead sponsor
Texas Cardiac Arrhythmia Research Foundation
Other
Eligibility
Not listed
Enrollment
40 participants
Timeline
2019 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2019 · Synced Sep 14, 2026, 6:03 AM EDT
Recruiting Not applicable Interventional

DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis

NCT05701917
View directory record Official record
Conditions
Venous Thromboembolism, Deep Venous Thrombosis, Post-Thrombotic Syndrome
Interventions
ClotTriever System, Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.
Device · Drug
Lead sponsor
Inari Medical
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
48
States / cities
Scottsdale, Arizona • Tucson, Arizona • Orange, California + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 14, 2026, 6:03 AM EDT
Withdrawn Phase 2 Interventional

Safety of Heparin in Patients With Septic Shock

NCT01234285
View directory record Official record
Conditions
Sepsis
Interventions
heparin
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Sep 14, 2026, 6:03 AM EDT
Completed Phase 2 Interventional

Anticoagulation With rNAPc2 to Eliminate MACE/TIMI 32

NCT00116012
View directory record Official record
Conditions
Coronary Disease
Interventions
rNAPc2
Drug
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 28, 2006 · Synced Sep 14, 2026, 6:03 AM EDT
Completed Not applicable Interventional

A Pharmacogenetic Study of Warfarin Dosing, "The COUMA-GEN Study"

NCT00334464
View directory record Official record
Conditions
Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism
Interventions
Standard of care or genotyping dosing of warfarin dosing
Drug
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 20, 2008 · Synced Sep 14, 2026, 6:03 AM EDT
Completed No phase listed Observational

Multi-Center Human Alert Trial to Prevent DVT and PE

NCT00409136
View directory record Official record
Conditions
Pulmonary Embolism, Deep Vein Thrombosis, Cancer, Surgery
Interventions
Human Alert
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
2,496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
26
States / cities
Scottsdale, Arizona • Long Beach, California • Orange, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2009 · Synced Sep 14, 2026, 6:03 AM EDT
Completed No phase listed Observational

Global Anticoagulant Registry in the Field

NCT01090362
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Not listed
Lead sponsor
Thrombosis Research Institute
Other
Eligibility
18 Years and older
Enrollment
57,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Sep 14, 2026, 6:03 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban

NCT02207725
View directory record Official record
Conditions
Bleeding
Interventions
Andexanet, Placebo
Biological · Other
Lead sponsor
Portola Pharmaceuticals
Industry
Eligibility
50 Years to 75 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 7, 2023 · Synced Sep 14, 2026, 6:03 AM EDT
Completed Phase 3 Interventional Results available

Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy

NCT03080883
View directory record Official record
Conditions
Cerebral Vein Thrombosis, Deep Vein Thrombosis, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Pulmonary Embolism, Splanchnic Vein Thrombosis
Interventions
Apixaban
Drug
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
32
States / cities
Scottsdale, Arizona • Washington D.C., District of Columbia • Jacksonville, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated May 17, 2025 · Synced Sep 14, 2026, 6:03 AM EDT
Completed No phase listed Observational

CoaguChek XS in Antiphospholipid Antibody Syndrome (APL) Patients

NCT02139072
View directory record Official record
Conditions
Antiphospholipid Antibody Syndrome
Interventions
CoaguChek XS, Standard Lab Draw
Device · Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 3, 2016 · Synced Sep 14, 2026, 6:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Use of Activated Recombinant Human Factor VII to Reduce Bleeding Caused by Warfarin Treatment

NCT01561937
View directory record Official record
Conditions
Haemostasis, Healthy
Interventions
warfarin, eptacog alfa (activated), placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older · Male only
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 24, 2016 · Synced Sep 14, 2026, 6:03 AM EDT
Not yet recruiting Phase 3 Interventional

Restarting Anticoagulation After Traumatic Intracranial Hemorrhage

NCT04229758
View directory record Official record
Conditions
Hemorrhage, Intracranial Hemorrhages, Bleeding, Trauma
Interventions
Anticoagulants
Drug
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Sep 14, 2026, 6:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Improving the Quality of Care for Atrial Fibrillation by Promoting Patient-Centered Decision Making

NCT00829478
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Decision Aid for Atrial Fibrillation, Usual Care
Behavioral · Other
Lead sponsor
VA Connecticut Healthcare System
Federal
Eligibility
45 Years and older
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 19, 2012 · Synced Sep 14, 2026, 6:03 AM EDT
Completed Not applicable Interventional Results available

Anticoagulation With Enhanced Gastrointestinal Safety

NCT05563714
View directory record Official record
Conditions
Upper Gastrointestinal Bleeding, Peptic Ulcer Hemorrhage, Anticoagulant-induced Bleeding
Interventions
Clinician Notification with Nurse Facilitation (CNNF), Wait list control
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Sep 14, 2026, 6:03 AM EDT
Terminated Not applicable Interventional Results available

Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation

NCT02928497
View directory record Official record
Conditions
Stroke
Interventions
WATCHMAN LAAC Device Implant, Single Antiplatelet Therapy or No Therapy (Control)
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
71
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 14, 2026, 6:03 AM EDT
Completed No phase listed Observational

Risk Factors for Venous Thromboembolism in the Community

NCT00011180
View directory record Official record
Conditions
Cardiovascular Diseases, Thromboembolism
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
Not listed
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 5, 2012 · Synced Sep 14, 2026, 6:03 AM EDT
Terminated Phase 3 Interventional

Comparison of Anticoagulation for All-comers Undergoing Percutaneous Coronary Revascularization Trial

NCT02448550
View directory record Official record
Conditions
Percutaneous Coronary Intervention
Interventions
Bivalirudin, Unfractionated heparin
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Sep 14, 2026, 6:03 AM EDT
Completed Not applicable Interventional Results available

Keep it SIMPLE: Improving Anti-Coagulation Medication Adherence

NCT02690649
View directory record Official record
Conditions
Atrial Fibrillation, Medication Adherence
Interventions
Health Messaging (Non-Procedural)
Other
Lead sponsor
Tammy Toscos
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Sep 14, 2026, 6:03 AM EDT
Completed Phase 4 Interventional

FREEDOM COVID-19 Anticoagulation Strategy

NCT04512079
View directory record Official record
Conditions
COVID-19, SARS-CoV-2
Interventions
Enoxaparin, Apixaban
Drug
Lead sponsor
Valentin Fuster
Other
Eligibility
18 Years and older
Enrollment
3,460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Sep 14, 2026, 6:03 AM EDT
Completed Not applicable Interventional

Rural Hospital-Level Care at Home for Acutely Ill Adults

NCT05256303
View directory record Official record
Conditions
Infections, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma, Gout Flare, Chronic Kidney Diseases, Hypertensive Urgency, Atrial Fibrillation Rapid, Anticoagulation, Diabetes and Its Complications, End of Life/Desires Only Medical Management
Interventions
Home Hospital care, Traditional Hospital care
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Quincy, Illinois • Hazard, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Sep 14, 2026, 6:03 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Applying Pharmacogenetic Algorithms to Individualize Dosing of Warfarin

NCT00927862
View directory record Official record
Conditions
Thromboembolism
Interventions
IWPC adapted genotype-guided dosing algorithm for warfarin, Modified IWPC genetic-guided warfarin dosing algorithm, Standard of care treatment
Genetic · Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
2,415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 24, 2012 · Synced Sep 14, 2026, 6:03 AM EDT